QNCX Stock — Quince Therapeutics Inc.: Cash, EV, Pipeline

Share price

$29.48

Market cap

$30.0M

Cash

$116.0M

Enterprise value

-$86.0M

Balance sheet

Cash	$116.0M
Debt	$0.0M
Net cash	$116.0M
Enterprise value	-$86.0M
Basic shares	1.0M shares
Fully diluted shares	17.1M shares
Fully diluted market cap	$503.6M
Cash per share	$115.98

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading QNCX daily closes…

Loading price history…

Pipeline assets

LAM-001

Phase 2 · Active Modality: inhaled dry powder formulation

Target mTOR (mammalian target of rapamycin)

Partnerships Orphai Therapeutics (acquired May 18, 2026)

Indications

pulmonary hypertension associated with interstitial lung disease (Phase 2b) (Stage not disclosed)
bronchiolitis obliterans syndrome post lung transplant (Phase 2) (Stage not disclosed)
sarcoidosis-associated pulmonary hypertension (Phase 2 to initiate late 2026) (Stage not disclosed)

Catalysts

— None
— None
— None

Status note Lead product candidate following the Orphai acquisition. Inhaled dry powder formulation of rapamycin designed for pulmonary delivery. Phase 2a trial completed in PAH, PH-ILD and SAPH. Company evaluating additional LAM-001 indications.

eDSP

Phase 3 · Terminated Modality: autologous red-blood-cell encapsulated drug (AIDE platform)

Indications

ataxia-telangiectasia (Stage not disclosed)

Status note Pivotal Phase 3 NEAT trial completed January 2026; primary endpoints did not reach statistical significance. Company discontinued development of eDSP in A-T and all other indications; related IPR&D was fully impaired and contingent consideration reduced to zero.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	72,251	+72,251	0.22%	2026-08-14
ADAR1 Capital Management	0	-50,100	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

QNCX — Quince Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders